Picture of Fresh Tracks Therapeutics logo

FRTX — Fresh Tracks Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapTurnaround

Brickell Biotech Inc expected to post a loss of 10  cents a share - Earnings Preview

* Brickell Biotech Inc  BBI.OQ   BBI.O  is expected to show
a rise
in quarterly revenue when it reports  results on March 7
(estimated). 
    * The Boulder Colorado-based  company is expected to report 
a
458.0% increase in revenue to $150.67 thousand from $27 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Brickell Biotech
Inc is
for a loss of 10 cents per share. For the same quarter last
year, the company reported a loss of 15 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Brickell
Biotech
Inc is $4​, about 94.6% above​ its last closing price
of $0.21. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021              -0.12      -0.16     Missed  -28
 Jun. 30 2021  -0.14       -0.12      -0.16     Missed  -28
 Mar. 31 2021  -0.11       -0.11      -0.15     Missed  -30.4​
 Dec. 31 2020  -0.09       -0.09      -0.15     Missed  -66.7
 ​​Sep.        -0.19       -0.18      -0.15     Beat    18.9
 30 2020                                                
                                                        ​
                                      -1.37             
 This summary was machine generated March 4 at 22:19 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Fresh Tracks Therapeutics

See all news